Potassium Channel-related Epilepsy: Pathogenesis and Clinical Features

Overview

Journal Epilepsia Open

Date 2024 Apr 1

PMID 38560778

Authors

Tong Zhao

Le Wang

Fang Chen

Affiliations

Soon will be listed here.

Abstract

Variants in potassium channel-related genes are one of the most important mechanisms underlying abnormal neuronal excitation and disturbances in the cellular resting membrane potential. These variants can cause different forms of epilepsy, which can seriously affect the physical and mental health of patients, especially those with refractory epilepsy or status epilepticus, which are common among pediatric patients and are potentially life-threatening. Variants in potassium ion channel-related genes have been reported in few studies; however, to our knowledge, no systematic review has been published. This study aimed to summarize the epilepsy phenotypes, functional studies, and pharmacological advances associated with different potassium channel gene variants to assist clinical practitioners and drug development teams to develop evidence-based medicine and guide research strategies. PubMed and Google Scholar were searched for relevant literature on potassium channel-related epilepsy reported in the past 5-10 years. Various common potassium ion channel gene variants can lead to heterogeneous epilepsy phenotypes, and functional effects can result from gene deletions and compound effects. Administration of select anti-seizure medications is the primary treatment for this type of epilepsy. Most patients are refractory to anti-seizure medications, and some novel anti-seizure medications have been found to improve seizures. Use of targeted drugs to correct aberrant channel function based on the type of potassium channel gene variant can be used as an evidence-based pathway to achieve precise and individualized treatment for children with epilepsy. PLAIN LANGUAGE SUMMARY: In this article, the pathogenesis and clinical characteristics of epilepsy caused by different types of potassium channel gene variants are reviewed in the light of the latest research literature at home and abroad, with the expectation of providing a certain theoretical basis for the diagnosis and treatment of children with this type of disease.

Citing Articles

Potassium channel-related epilepsy: Pathogenesis and clinical features.

Zhao T, Wang L, Chen F Epilepsia Open. 2024; 9(3):891-905.

PMID: 38560778 PMC: 11145612. DOI: 10.1002/epi4.12934.

References

Masnada S, Hedrich U, Gardella E, Schubert J, Kaiwar C, Klee E . Clinical spectrum and genotype-phenotype associations of KCNA2-related encephalopathies. Brain. 2017; 140(9):2337-2354. DOI: 10.1093/brain/awx184. View

Sausbier M, Hu H, Arntz C, Feil S, Kamm S, Adelsberger H . Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency. Proc Natl Acad Sci U S A. 2004; 101(25):9474-8. PMC: 439001. DOI: 10.1073/pnas.0401702101. View

Thijs R, Surges R, OBrien T, Sander J . Epilepsy in adults. Lancet. 2019; 393(10172):689-701. DOI: 10.1016/S0140-6736(18)32596-0. View

Nascimento F, Andrade D . Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations. Epileptic Disord. 2016; 18(S2):135-138. DOI: 10.1684/epd.2016.0859. View

Syrbe S, Hedrich U, Riesch E, Djemie T, Muller S, Moller R . De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat Genet. 2015; 47(4):393-399. PMC: 4380508. DOI: 10.1038/ng.3239. View

Miceli F, Soldovieri M, Ambrosino P, De Maria M, Migliore M, Migliore R . Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. J Neurosci. 2015; 35(9):3782-93. PMC: 6605567. DOI: 10.1523/JNEUROSCI.4423-14.2015. View

Evely K, Pryce K, Bhattacharjee A . The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype. Neuroscience. 2017; 351:65-70. PMC: 5479566. DOI: 10.1016/j.neuroscience.2017.03.035. View

Allen A, Cossette P, Delanty N, Eichler E, Goldstein D, Han Y . De novo mutations in epileptic encephalopathies. Nature. 2013; 501(7466):217-21. PMC: 3773011. DOI: 10.1038/nature12439. View

Milh M, Lacoste C, Cacciagli P, Abidi A, Sutera-Sardo J, Tzelepis I . Variable clinical expression in patients with mosaicism for KCNQ2 mutations. Am J Med Genet A. 2015; 167A(10):2314-8. DOI: 10.1002/ajmg.a.37152. View

10.

Kortum F, Caputo V, Bauer C, Stella L, Ciolfi A, Alawi M . Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome. Nat Genet. 2015; 47(6):661-7. DOI: 10.1038/ng.3282. View

11.

Curran M . Potassium ion channels and human disease: phenotypes to drug targets?. Curr Opin Biotechnol. 1999; 9(6):565-72. DOI: 10.1016/s0958-1669(98)80133-x. View

12.

Kinali M, Jungbluth H, Eunson L, Sewry C, Manzur A, Mercuri E . Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscul Disord. 2004; 14(10):689-93. DOI: 10.1016/j.nmd.2004.06.007. View

13.

Karalok Z, Megaro A, Cenciarini M, Guven A, Hasan S, Taskin B . Identification of a New Mutation Underlying Regressive Episodic Ataxia Type I. Front Neurol. 2018; 9:587. PMC: 6094999. DOI: 10.3389/fneur.2018.00587. View

14.

Kohling R, Wolfart J . Potassium Channels in Epilepsy. Cold Spring Harb Perspect Med. 2016; 6(5). PMC: 4852798. DOI: 10.1101/cshperspect.a022871. View

15.

Aubert Mucca M, Patat O, Whalen S, Arnaud L, Barcia G, Buratti J . Patients with -related intellectual disability without distinctive features of Zimmermann-Laband/Temple-Baraitser syndrome. J Med Genet. 2021; 59(5):505-510. DOI: 10.1136/jmedgenet-2020-107511. View

16.

Gong P, Jiao X, Yu D, Yang Z . Case Report: Causative Variants of for Developmental and Epileptic Encephalopathy. Front Genet. 2021; 12:649556. PMC: 8277933. DOI: 10.3389/fgene.2021.649556. View

17.

Corbett M, Bellows S, Li M, Carroll R, Micallef S, Carvill G . Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy. Neurology. 2016; 87(19):1975-1984. PMC: 5109949. DOI: 10.1212/WNL.0000000000003309. View

18.

Kuersten M, Tacke M, Gerstl L, Hoelz H, Stulpnagel C, Borggraefe I . Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. Eur J Med Genet. 2019; 63(1):103628. DOI: 10.1016/j.ejmg.2019.02.001. View

19.

Manole A, Mannikko R, Hanna M, Kullmann D, Houlden H . De novo KCNA2 mutations cause hereditary spastic paraplegia. Ann Neurol. 2016; 81(2):326-328. DOI: 10.1002/ana.24866. View

20.

Hedrich U, Lauxmann S, Wolff M, Synofzik M, Bast T, Binelli A . 4-Aminopyridine is a promising treatment option for patients with gain-of-function -encephalopathy. Sci Transl Med. 2021; 13(609):eaaz4957. DOI: 10.1126/scitranslmed.aaz4957. View